Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
RAPSON
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
- NCT03230734 ↗
- Unknown
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Standard
We haven't built an HCP commentary report on RAPSON (radium-223 plus docetaxel in symptomatic bone-only metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RAPSON so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 11 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Radium-223; Docetaxel
- Arms
- Treatment Arm A · Experimental
- Treatment Arm B · Experimental
- Enrollment
- 70 (estimated)
- Primary outcomes
- health-related quality of life (HRQoL) clinical benefit
- health-related quality of life (HRQoL ) clinical benefit
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS with Bayer
- Start
- Sep 1, 2017
- Primary completion
- Jul 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03230734 · updated Sep 27, 2024